EC
AKRO

EntryPoint Capital’s Akero Therapeutics AKRO Stock Holding History

EntryPoint Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,311
Closed -$101K – 612
2024
Q2 		$101K Buy
+4,311
New +$92.2K 0.15% 315
2024
Q1 		– Sell
-1,239
Closed -$28.9K – 1398
2023
Q4 		$28.9K Buy
+1,239
New +$24.4K 0.03% 939

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EntryPoint Capital's AKRO Position: Q3 2024 in Review

EntryPoint Capital sold out of Akero Therapeutics (AKRO) in Q3 2024, closing a stake of 4,311 shares — an estimated $101K sold.

EntryPoint Capital first reported a position in AKRO in Q4 2023 and held it in 2 quarters. The position peaked at $101K in Q2 2024. 168 funds tracked by Wall St. Rank hold AKRO as of Q3 2024.

  • EntryPoint Capital reported no remaining Akero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 4,311 Akero Therapeutics shares in Q3 2024, an estimated $101K.
  • EntryPoint Capital first reported a position in Akero Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Akero Therapeutics position peaked at $101K in Q2 2024.
  • 168 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.